New Zealand and international experts in melanoma will gather in Auckland on 2-3 November for the 2018 Melanoma Summit.
The National Melanoma Summit is hosted by the Melanoma Network of New Zealand with support from the Health Promotion Agency.
The fifth event of its kind, the 2018 New Zealand Melanoma Summit will examine and discuss recent developments in melanoma control and identify priorities for action for New Zealand.
New Zealand continues to have one of the highest incidence rates of melanoma in the world.
The programme features a diverse range of experts recognised internationally for their contribution to melanoma control and is an opportunity to hear about recent developments, identify priorities for action and work more closely to reduce the impact and incidence of melanoma in New Zealand.
• Professor David Whiteman, Senior Scientist and Deputy Director of the QIMR Berghofer Medical Research Institute in Brisbane. Professor Whiteman is a medical epidemiologist and pioneer of molecular approaches to melanoma.
• Professor John Kelly AM, Melbourne dermatologist and founder, in 1994, of Victoria’s largest multidisciplinary treatment service for melanoma, the Victorian Melanoma Service at the Alfred Hospital.
• Professor John Thompson, Professor of Melanoma and Surgical Oncology at the University of Sydney. Professor Thompson is internationally recognised for his leadership in developing the sentinel node biopsy technique in the management of melanoma. He is chair of the working group responsible for updating the Clinical Practice Guidelines for the Management of Cutaneous Melanoma in Australia and New Zealand, and is an Inaugural Fellow of the Australian Academy of Health and Medical Sciences.
• Associate Professor Victoria Atkinson, senior staff specialist medical oncologist at the Princess Alexandra Hospital in Brisbane, Australia. She also works in private practice at Greenslopes Private Hospital and is affiliated with the University of Queensland Clinical School of Medicine where she was appointed as an Associate Professor in 2016. She has extensive experience with targeted therapies for melanoma including Vemurafenib, Dabrafenib, Trametinib, Ipilimumab and Nivolumab, and is principal investigator or co-investigator in clinical trials at both Princess Alexandra Hospital and Greenslopes Private Hospital.
The Summit venue is the Cordis Hotel, 83 Symonds Street, Auckland. More information is available here.